- Home
- NUVL vs TSEM Comparison
NUVL vs TSEM Comparison
Compare NUVL & TSEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- TSEM
- Stock Information
- Founded
- NUVL 2017
- TSEM 1993
- Country
- NUVL United States
- TSEM Israel
- Employees
- NUVL N/A
- TSEM N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- TSEM Semiconductors
- Sector
- NUVL Health Care
- TSEM Technology
- Exchange
- NUVL Nasdaq
- TSEM Nasdaq
- Market Cap
- NUVL 7.1B
- TSEM 8.3B
- IPO Year
- NUVL 2021
- TSEM 1994
- Fundamental
- Price
- NUVL $109.19
- TSEM $91.48
- Analyst Decision
- NUVL Strong Buy
- TSEM Strong Buy
- Analyst Count
- NUVL 13
- TSEM 5
- Target Price
- NUVL $133.85
- TSEM $107.40
- AVG Volume (30 Days)
- NUVL 734.4K
- TSEM 1.9M
- Earning Date
- NUVL 10-30-2025
- TSEM 11-10-2025
- Dividend Yield
- NUVL N/A
- TSEM N/A
- EPS Growth
- NUVL N/A
- TSEM N/A
- EPS
- NUVL N/A
- TSEM 1.73
- Revenue
- NUVL N/A
- TSEM $1,513,089,000.00
- Revenue This Year
- NUVL N/A
- TSEM $10.78
- Revenue Next Year
- NUVL N/A
- TSEM $12.76
- P/E Ratio
- NUVL N/A
- TSEM $56.97
- Revenue Growth
- NUVL N/A
- TSEM 8.03
- 52 Week Low
- NUVL $55.54
- TSEM $28.64
- 52 Week High
- NUVL $112.88
- TSEM $106.74
- Technical
- Relative Strength Index (RSI)
- NUVL 66.08
- TSEM 55.01
- Support Level
- NUVL $93.05
- TSEM $94.10
- Resistance Level
- NUVL $112.53
- TSEM $106.74
- Average True Range (ATR)
- NUVL 5.84
- TSEM 6.27
- MACD
- NUVL 1.06
- TSEM -0.21
- Stochastic Oscillator
- NUVL 84.34
- TSEM 42.78
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About TSEM Tower Semiconductor Ltd.
Tower Semiconductor Ltd is a pure-play specialty foundry that manufactures semiconductors. As a pure-play foundry, it focuses on producing integrated circuits (ICs), based on the design specifications of customers. The company's line of integrated circuits is incorporated into a range of products and markets, including consumer electronics, personal computers, communications, automotive, and industrial and medical device products. It produces ICs alongside wholly-owned subsidiaries through fabrication facilities located in Japan. The company has a geographical presence in the USA, Japan, Asia (other than Japan), and Europe.